since its high degree of diversification across platforms offsets the variable outcomes for drug development and competitive challenges to the firm's leading products. Our rating for GSK is not ...

The Cambridge-GSK Translational Immunology Collaboration (CG-TIC ... We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty ...

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 ...

GlaxoSmithKline ( (GSK) ) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

Johnson & Johnson announced at its booth the China market launch of INVEGA HAFYERA, a medicine for the treatment of ...

GSK is delivering consistent financial performance ... which Deborah will cover shortly. Respiratory and immunology products were up 14%, and Nucala IL5 biologic treatment was up 12%.

These products broadly target infectious diseases, HIV, respiratory and immunology, oncology, and other smaller "opportunity-driven" IPs. In my view, you can think of GSK as a company with a set ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The Federal Government is advancing its commitment to ensure a self-sustaining healthcare system by collaborating with ...